Knowledge and Views of Patients With Cardiovascular Disease Toward Pharmacogenomics in The United Arab Emirates

ABSTRACT Pharmacogenomics (PGx) can potentially tailor medication prescriptions to the genetic profiles of individuals, enhancing treatment outcomes and minimizing adverse drug reactions. This study assessed cardiovascular disease (CVD) patients' knowledge and views toward PGx testing in the Un...

Full description

Saved in:
Bibliographic Details
Main Authors: Maram O. Abbas, Azhar T. Rahma, Iffat Elbarazi, Bassam R. Ali, George P. Patrinos, Farah Nagy, Alya Osman, Reem K. Alneyadi, Anwar S. Alshamsi, Mohamed Alraqabani, Zeina Al‐Mahayri, Fatma Al‐Maskari
Format: Article
Language:English
Published: Wiley 2025-08-01
Series:Clinical and Translational Science
Subjects:
Online Access:https://doi.org/10.1111/cts.70300
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849227184125771776
author Maram O. Abbas
Azhar T. Rahma
Iffat Elbarazi
Bassam R. Ali
George P. Patrinos
Farah Nagy
Alya Osman
Reem K. Alneyadi
Anwar S. Alshamsi
Mohamed Alraqabani
Zeina Al‐Mahayri
Fatma Al‐Maskari
author_facet Maram O. Abbas
Azhar T. Rahma
Iffat Elbarazi
Bassam R. Ali
George P. Patrinos
Farah Nagy
Alya Osman
Reem K. Alneyadi
Anwar S. Alshamsi
Mohamed Alraqabani
Zeina Al‐Mahayri
Fatma Al‐Maskari
author_sort Maram O. Abbas
collection DOAJ
description ABSTRACT Pharmacogenomics (PGx) can potentially tailor medication prescriptions to the genetic profiles of individuals, enhancing treatment outcomes and minimizing adverse drug reactions. This study assessed cardiovascular disease (CVD) patients' knowledge and views toward PGx testing in the United Arab Emirates (UAE). A cross‐sectional study was conducted among CVD patients attending multiple clinics using a validated, culturally adapted, and piloted bilingual questionnaire. Participants were invited via phone calls or in‐person contact at clinics. Data analysis was conducted using SPSS V.29, incorporating descriptive statistics and multivariable logistic regression. A total of 425 responses were analyzed; 67.5% were over 50 years old, and 67.5% held a bachelor's degree. Chronic diseases, excluding CVD, affected 65.2%, with 58.1% reporting medication side effects and 36.5% was hospitalized due to these effects. Knowledge varied, with 55.3% demonstrating good knowledge; 75.3% recognized DNA as gene‐based, while 47.5% understood PGx for predicting medication responses. Participants were grouped into three PGx perception clusters: Cluster 1 (33.17%) concerned about risks but valued PGx, Cluster 2 (40.23%) worried about privacy/costs, and Cluster 3 (26.58%) confident in PGx benefits. Safety was the top priority for 60.2% of respondents, 34.8% would not pay for PGx tets, and 35.3% preferred preemptive testing. Regression linked higher PGx knowledge to females, non‐healthcare workers, those with genetic diseases, and those hospitalized for side effects (p < 0.05). The study highlights a need for educational initiatives in the UAE to improve PGx literacy among CVD patients. The findings suggest that targeted awareness campaigns, policy interventions addressing privacy, and financial support could promote PGx wider adoption.
format Article
id doaj-art-dba33c9fde9d48ea96a1448b20a875c6
institution Kabale University
issn 1752-8054
1752-8062
language English
publishDate 2025-08-01
publisher Wiley
record_format Article
series Clinical and Translational Science
spelling doaj-art-dba33c9fde9d48ea96a1448b20a875c62025-08-23T17:10:42ZengWileyClinical and Translational Science1752-80541752-80622025-08-01188n/an/a10.1111/cts.70300Knowledge and Views of Patients With Cardiovascular Disease Toward Pharmacogenomics in The United Arab EmiratesMaram O. Abbas0Azhar T. Rahma1Iffat Elbarazi2Bassam R. Ali3George P. Patrinos4Farah Nagy5Alya Osman6Reem K. Alneyadi7Anwar S. Alshamsi8Mohamed Alraqabani9Zeina Al‐Mahayri10Fatma Al‐Maskari11Institute of Public Health, College of Medicine and Health Sciences United Arab Emirates University Al Ain UAEInstitute of Public Health, College of Medicine and Health Sciences United Arab Emirates University Al Ain UAEInstitute of Public Health, College of Medicine and Health Sciences United Arab Emirates University Al Ain UAEDepartment of Genetics and Genomics, College of Medicine and Health Sciences United Arab Emirates University Al Ain UAEDepartment of Genetics and Genomics, College of Medicine and Health Sciences United Arab Emirates University Al Ain UAEDepartment of Pharmacy Practice Dubai Pharmacy College Dubai UAEDepartment of Pharmacy Practice Dubai Pharmacy College Dubai UAEInstitute of Public Health, College of Medicine and Health Sciences United Arab Emirates University Al Ain UAEInstitute of Public Health, College of Medicine and Health Sciences United Arab Emirates University Al Ain UAERashid Hospital Dubai Health Authority Dubai UAECollege of Health Sciences Abu Dhabi University Abu Dhabi UAEInstitute of Public Health, College of Medicine and Health Sciences United Arab Emirates University Al Ain UAEABSTRACT Pharmacogenomics (PGx) can potentially tailor medication prescriptions to the genetic profiles of individuals, enhancing treatment outcomes and minimizing adverse drug reactions. This study assessed cardiovascular disease (CVD) patients' knowledge and views toward PGx testing in the United Arab Emirates (UAE). A cross‐sectional study was conducted among CVD patients attending multiple clinics using a validated, culturally adapted, and piloted bilingual questionnaire. Participants were invited via phone calls or in‐person contact at clinics. Data analysis was conducted using SPSS V.29, incorporating descriptive statistics and multivariable logistic regression. A total of 425 responses were analyzed; 67.5% were over 50 years old, and 67.5% held a bachelor's degree. Chronic diseases, excluding CVD, affected 65.2%, with 58.1% reporting medication side effects and 36.5% was hospitalized due to these effects. Knowledge varied, with 55.3% demonstrating good knowledge; 75.3% recognized DNA as gene‐based, while 47.5% understood PGx for predicting medication responses. Participants were grouped into three PGx perception clusters: Cluster 1 (33.17%) concerned about risks but valued PGx, Cluster 2 (40.23%) worried about privacy/costs, and Cluster 3 (26.58%) confident in PGx benefits. Safety was the top priority for 60.2% of respondents, 34.8% would not pay for PGx tets, and 35.3% preferred preemptive testing. Regression linked higher PGx knowledge to females, non‐healthcare workers, those with genetic diseases, and those hospitalized for side effects (p < 0.05). The study highlights a need for educational initiatives in the UAE to improve PGx literacy among CVD patients. The findings suggest that targeted awareness campaigns, policy interventions addressing privacy, and financial support could promote PGx wider adoption.https://doi.org/10.1111/cts.70300cardiovascular diseasespatient knowledge and attitudespharmacogenomicsUnited Arab Emirates
spellingShingle Maram O. Abbas
Azhar T. Rahma
Iffat Elbarazi
Bassam R. Ali
George P. Patrinos
Farah Nagy
Alya Osman
Reem K. Alneyadi
Anwar S. Alshamsi
Mohamed Alraqabani
Zeina Al‐Mahayri
Fatma Al‐Maskari
Knowledge and Views of Patients With Cardiovascular Disease Toward Pharmacogenomics in The United Arab Emirates
Clinical and Translational Science
cardiovascular diseases
patient knowledge and attitudes
pharmacogenomics
United Arab Emirates
title Knowledge and Views of Patients With Cardiovascular Disease Toward Pharmacogenomics in The United Arab Emirates
title_full Knowledge and Views of Patients With Cardiovascular Disease Toward Pharmacogenomics in The United Arab Emirates
title_fullStr Knowledge and Views of Patients With Cardiovascular Disease Toward Pharmacogenomics in The United Arab Emirates
title_full_unstemmed Knowledge and Views of Patients With Cardiovascular Disease Toward Pharmacogenomics in The United Arab Emirates
title_short Knowledge and Views of Patients With Cardiovascular Disease Toward Pharmacogenomics in The United Arab Emirates
title_sort knowledge and views of patients with cardiovascular disease toward pharmacogenomics in the united arab emirates
topic cardiovascular diseases
patient knowledge and attitudes
pharmacogenomics
United Arab Emirates
url https://doi.org/10.1111/cts.70300
work_keys_str_mv AT maramoabbas knowledgeandviewsofpatientswithcardiovasculardiseasetowardpharmacogenomicsintheunitedarabemirates
AT azhartrahma knowledgeandviewsofpatientswithcardiovasculardiseasetowardpharmacogenomicsintheunitedarabemirates
AT iffatelbarazi knowledgeandviewsofpatientswithcardiovasculardiseasetowardpharmacogenomicsintheunitedarabemirates
AT bassamrali knowledgeandviewsofpatientswithcardiovasculardiseasetowardpharmacogenomicsintheunitedarabemirates
AT georgeppatrinos knowledgeandviewsofpatientswithcardiovasculardiseasetowardpharmacogenomicsintheunitedarabemirates
AT farahnagy knowledgeandviewsofpatientswithcardiovasculardiseasetowardpharmacogenomicsintheunitedarabemirates
AT alyaosman knowledgeandviewsofpatientswithcardiovasculardiseasetowardpharmacogenomicsintheunitedarabemirates
AT reemkalneyadi knowledgeandviewsofpatientswithcardiovasculardiseasetowardpharmacogenomicsintheunitedarabemirates
AT anwarsalshamsi knowledgeandviewsofpatientswithcardiovasculardiseasetowardpharmacogenomicsintheunitedarabemirates
AT mohamedalraqabani knowledgeandviewsofpatientswithcardiovasculardiseasetowardpharmacogenomicsintheunitedarabemirates
AT zeinaalmahayri knowledgeandviewsofpatientswithcardiovasculardiseasetowardpharmacogenomicsintheunitedarabemirates
AT fatmaalmaskari knowledgeandviewsofpatientswithcardiovasculardiseasetowardpharmacogenomicsintheunitedarabemirates